01—Abstract
Summary
Summary of the 8-K filed January 27, 2026. Cited figures are marked; the original filing is the authoritative source.
UnitedHealth Group reported full-year 2025 revenues of $447.6 billiona (up 12% year-over-year), GAAP diluted EPS of $13.23 and adjusted EPS of $16.35, with earnings from operations of $19.0 billion.
Fourth-quarter GAAP EPS was just $0.01b (adjusted $2.11), reflecting a $1.6 billion after-tax ($1.78 per share) charge covering final cyberattack costs, net portfolio divestitures, and restructuring. The adjusted medical care ratio rose to 88.9%, up 340 basis points year-over-year, driven by Medicare funding reductions, Inflation Reduction Act impacts, and elevated medical cost trends. UnitedHealthcare operating margin fell to 2.7% from 5.2%, while Optum Health swung to an operating loss of $278 million.
For 2026, management guides to revenues above $439.0 billionc (a roughly 2% decline), earnings from operations above $24.0 billion, GAAP EPS above $17.10, and adjusted EPS above $17.75. The outlook assumes a consolidated medical care ratio of 88.8% (plus or minus 50 basis points, a 30 basis point improvement), and an operating cost ratio of 12.8%. Revenue shrinkage is intentional, reflecting planned membership attrition of roughly 2.3 to 2.8 million people across medical products, Optum Rx client losses, and Optum Health right-sizing.
Cash flow from operations is expected to exceed $18.0 billiond, and the debt-to-capital ratio remains on a path toward 40% in 2026. Investors should weigh the meaningful improvement in guided margins and earnings against the still-elevated medical cost pressure and the significant reliance on repricing and membership shrinkage to deliver it.
The results also include a substantial non-cash restructuring charge and ongoing reviews of business practices, which management says are still under way. Execution against the medical cost assumptions in 2026 will be the key test for the thesis.
02—Key points
Key Highlights
- FY2025 revenue of $447.6B (+12% YoY); GAAP diluted EPS $13.23 vs. adjusted EPS $16.35, a gap driven by the $1.78/share Q4 charge
- Q4 2025 GAAP EPS was only $0.01 (adjusted $2.11), with earnings from operations of just $0.4B vs. $7.8B a year earlier
- Adjusted medical care ratio rose to 88.9% in FY2025 (+340 bps YoY); Medicare funding cuts, IRA Part D impacts, and rising medical trends drove the increase
- UnitedHealthcare operating margin fell to 2.7% from 5.2%; Optum Health posted a $(278)M GAAP operating loss, while Optum Rx earnings rose to $7.2B
- 2026 guidance: revenue >$439.0B (≈-2%), operating earnings >$24.0B, GAAP EPS >$17.10, adjusted EPS >$17.75, and operating cash flow >$18.0B
- 2026 outlook targets an 88.8% medical care ratio (±50 bps, ~30 bps improvement), with planned membership contraction of roughly 2.3-2.8M people served
- Debt-to-capital ratio at 43.9% at year-end 2025, with management targeting 40.0% in 2026; cash flow of $19.7B exceeded net income by 1.5x, partly from timing
03—Questions
Frequently Asked Questions
Why did fourth-quarter 2025 GAAP earnings fall so sharply?
Q4 2025 GAAP net earnings attributable to shareholders were only $10 million ($0.01 per share), versus $5.5 billion a year earlier. The drop reflects a pre-tax restructuring and other charge of $2.5 billion, $799 million of final cyberattack costs, and net portfolio divestitures that were partly offset by a $442 million gain. Management states the charge, totaling $1.6 billion after tax, was largely non-cash and excluded from adjusted EPS.
What is driving the rise in the medical care ratio and how does 2026 address it?
The adjusted medical care ratio rose to 88.9% in 2025 from 85.5% in 2024, due to CMS Medicare funding reductions, Inflation Reduction Act changes, and accelerating medical cost trends. For 2026, management guides to 88.8% (±50 bps), citing repricing across the enterprise and a planned shrinkage of unprofitable membership. Achieving this depends on repricing taking effect and on medical cost trends moderating, which the filing does not quantify.
Why is 2026 revenue guided lower despite higher earnings?
Revenue is projected to fall about 2% to more than $439.0 billion as the company intentionally shrinks unprofitable business. UnitedHealthcare membership is expected to decline by roughly 2.3-2.8 million people, Optum Rx is losing corresponding volume, and Optum Health is being right-sized. Management frames this as margin-accretive, with consolidated net margin expected to improve to about 3.6% from 2.7%.
How much of the 2025 results should investors consider non-recurring?
Management excludes several items from adjusted results, including $799 million of cyberattack direct costs, $2.5 billion of restructuring and other charges, and net portfolio divestiture effects. The filing also notes that the company expects to continue taking further reviews and actions, and that significant divestiture and valuation items will be excluded in future periods. Investors should monitor whether restructuring charges recur, since they are a substantial share of the gap between GAAP and adjusted EPS.
What is the company's balance sheet and cash flow position?
Operating cash flow was $19.7 billion in 2025, down from $24.2 billion in 2024, but above net income, partly due to timing of payments expected in 2026. The debt-to-capital ratio was 43.9%, versus a 40% long-term target that management expects to reach in 2026. The 2026 plan calls for dividends of about $8.0 billion, share repurchases of about $2.5 billion (down from $5.5 billion in 2025), and capital expenditures of about $3.8 billion.
04—Continue